Viking Therapeutics (NASDAQ:VKTX) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03, Morningstar.com reports.
Shares of VKTX stock opened at $7.72 on Friday. Viking Therapeutics has a one year low of $3.69 and a one year high of $24.00. The company has a market capitalization of $570.25 million, a P/E ratio of -9.77 and a beta of 2.73.
Several research firms have recently issued reports on VKTX. Raymond James lowered their price objective on Viking Therapeutics from $43.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Thursday. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a report on Thursday. Maxim Group reduced their target price on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday. BidaskClub cut Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, March 6th. Finally, Leerink Swann initiated coverage on Viking Therapeutics in a report on Friday, February 22nd. They issued a “market perform” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $22.88.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
See Also: Diversification Important in Investing
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.